Skip to main content
. 2015 Jul 9;47(3):891–899. doi: 10.3892/ijo.2015.3077

Figure 4.

Figure 4

In vivo antitumor activities of YM155 on human MFH/UPS xenografts (Nara-H). (A) Tumor volume (mm3) and body weight (g) in YM155-treated (2 mg or 4 mg) or control mice was monitored for 14 days. Data represent mean ± SE of at least three independent experiments (*p<0.05, **p<0.01). (B) Survivin mRNA expression in YM155-treated or control tumors was evaluated by qPCR. Data represent mean ± SE of at least three independent experiments (*p<0.05). (C) Immunoblot analysis for survivin in YM155-treated or control tumors. (D) Correlation between apoptotic activity and survivin expression in YM155-4 mg-treated or control tumors was assessed by FACS analysis (red, control; blue, YM155-4 mg). (E) DNA fragmentation analysis of tumor tissues from YM155-4 mg-treated and control mice by immunofluorescence staining [blue, nuclear (DAPI); green, apoptosis nuclear (APO-DIRECT)].